Assembly Biosciences, Inc.
ASMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.02 | -0.00 | -0.12 |
| FCF Yield | -53.98% | 49.93% | -134.38% | -7.42% |
| EV / EBITDA | -1.31 | -0.43 | -0.15 | -13.73 |
| Quality | ||||
| ROIC | -63.76% | -65.45% | -100.93% | -71.79% |
| Gross Margin | 99.55% | -582.67% | 0.00% | 92.55% |
| Cash Conversion Ratio | 1.27 | -0.37 | 0.91 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 4.63% | -100.00% | -26.83% |
| Free Cash Flow Growth | -327.43% | 126.59% | 12.36% | -48.05% |
| Safety | ||||
| Net Debt / EBITDA | 0.78 | 0.27 | 0.53 | 0.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -15.30 | 0.00 | 0.00 |
| Cash Conversion Cycle | 5.12 | -25.11 | -1,827.20 | -2,063.08 |